Paul Tudor Jones's VRDN Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 62,184 shares of Viridian Therapeutics, Inc. (VRDN) worth $1.14 M, representing 0.00% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in VRDN, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 62,184 shares. Largest reduction occurred in Q1 2026, reducing 51,597 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Viridian Therapeutics (VRDN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Viridian Therapeutics (VRDN) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +62,184 | New Buy | 62,184 | $18.37 |
| Q1 2026 | -51,597 | Sold Out | 0 | $0.00 |
| Q4 2025 | +51,597 | New Buy | 51,597 | $31.12 |
| Q1 2025 | -38,367 | Sold Out | 0 | $0.00 |
| Q4 2024 | +1,106 | Add 2.97% | 38,367 | $19.17 |
| Q3 2024 | +37,261 | New Buy | 37,261 | $22.75 |
| Q1 2024 | -30,218 | Sold Out | 0 | $0.00 |
| Q4 2023 | +30,218 | New Buy | 30,218 | $21.78 |
| Q2 2023 | -24,110 | Sold Out | 0 | $0.00 |
| Q1 2023 | +24,110 | New Buy | 24,110 | $0.03 |
Paul Tudor Jones's Viridian Therapeutics Investment FAQs
Paul Tudor Jones first purchased Viridian Therapeutics, Inc. (VRDN) in Q1 2023, acquiring 24,110 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Viridian Therapeutics, Inc. (VRDN) for 10 quarters since Q1 2023.
Paul Tudor Jones's largest addition to Viridian Therapeutics, Inc. (VRDN) was in Q2 2026, adding 62,184 shares worth $1.14 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 62,184 shares of Viridian Therapeutics, Inc. (VRDN), valued at approximately $1.14 M.
As of the Q2 2026 filing, Viridian Therapeutics, Inc. (VRDN) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Viridian Therapeutics, Inc. (VRDN) was 62,184 shares, as reported at the end of Q2 2026.